We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Accepts Sandoz’s Application for Neulesta Biosimilar
EMA Accepts Sandoz’s Application for Neulesta Biosimilar
The European Medicines Agency has accepted Sandoz’s MAA for its biosimilar to Amgen’s Neulesta to help the body make white blood cells after receiving cancer medications.